With the aim of describing the role of ABCB1/MDR1/P-gp and the MDR phenotype in clinical GO resistance, Linenberger and colleagues analyzed pretreatment blast cells obtained from relapsed AML patients eligible for phase II clinical trials with GO [59]. The gene discussed is ABCB1; the disease is acute myeloid leukemia.